HCC1143 Cells

The HCC1143 cell line is derived from a human triple-negative breast cancer (TNBC), specifically lacking estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. This cell line is known for its use in modeling aggressive breast cancer phenotypes and understanding mechanisms underlying treatment resistance. HCC1143 exhibits distinct characteristics, including heterogeneity in cell subpopulations, contributing to its relevance in research focused on phenotypic plasticity and tumor cell state transitions. Studies utilizing HCC1143 have demonstrated that different cell states within the line can transition between luminal, basal, and mesenchymal differentiation states under therapeutic pressures, highlighting its role in studying therapy-induced phenotypic changes and drug resistance mechanisms.

HCC1143 cells have been used in various experimental contexts, including investigations of resistance mechanisms to chemotherapy agents like paclitaxel. Single-cell RNA sequencing (scRNA-seq) has revealed subpopulations with differential gene expression profiles linked to treatment resistance. For example, specific subpopulations such as AKR1C3+, IDO1+, and HEY1+ cells have shown increased representation following prolonged paclitaxel treatment, suggesting their role as drug-resistant phenotypes. These subtypes are associated with pathways involving reactive oxygen species (ROS), inflammatory responses, and cell cycle regulation, indicating complex adaptations that facilitate survival under chemotherapeutic stress.

Research on HCC1143 has also extended to targeted therapy studies. The application of inhibitors targeting components like ADAM-17 has shown potential in reducing the invasiveness and proliferation of this cell line, supporting its application as a model for testing novel anticancer strategies. These findings underscore HCC1143’s value for exploring both therapeutic responses and the underlying cellular dynamics that drive drug resistance in TNBC.